Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

36.98 +0.93 (+2.58%)

Official Closing Price Updated: 6:30 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

47 48 Next >

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

April 01, 2025

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

Via MarketBeat

1 Stock Under $50 on Our Watchlist and 2 to Turn Down

March 31, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

Is Hims & Hers Stock Too Cheap to Pass Up? ↗

March 29, 2025

This high-growth stock may be cheaper than you think.

Via The Motley Fool

Smart Money Is Betting Big In HIMS Options ↗

March 28, 2025

Via Benzinga

Check Out What Whales Are Doing With HIMS ↗

March 12, 2025

Via Benzinga

Should You Buy Hims & Hers Stock on the Dip? ↗

March 11, 2025

Via The Motley Fool

Forecasting The Future: 15 Analyst Projections For Hims & Hers Health ↗

March 06, 2025

Via Benzinga

Why Hims & Hers Stock Just Collapsed ↗

March 06, 2025

Via The Motley Fool

Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%? ↗

March 28, 2025

Via The Motley Fool

Topics Earnings

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped ↗

March 24, 2025

There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.

Via The Motley Fool

Hims & Hers Health's Options Frenzy: What You Need to Know ↗

March 19, 2025

Via Benzinga

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

March 18, 2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight...

Via StockStory

Topics Supply Chain

Market Whales and Their Recent Bets on HIMS Options ↗

March 06, 2025

Via Benzinga

Why Hims & Hers Stock Tumbled on Tuesday ↗

March 18, 2025

Bank of America just delivered an incredibly back-handed compliment to Hims & Hers stock.

Via The Motley Fool

2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

March 18, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

March 18, 2025

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

Via MarketBeat

Why Hims & Hers Stock Popped on Monday ↗

March 17, 2025

Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?

Via The Motley Fool

2 High-Flying Stocks with Exciting Potential and 1 to Turn Down

March 13, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers

March 13, 2025

From Defiance ETFs

Via GlobeNewswire

Why Hims & Hers Health Stock Just Popped ↗

March 11, 2025

Via The Motley Fool

4 Top Stocks to Buy Under $100 ↗

March 11, 2025

Here are four stocks to buy now that could offer investors upside in the short and long terms.

Via The Motley Fool

Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity? ↗

March 11, 2025

Shutting down an acquisition caught investor attention, but there's more to the story.

Via The Motley Fool

The State of Weight Loss Drugs ↗

March 10, 2025

Via The Motley Fool

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

March 10, 2025

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

Via MarketBeat

3 Cold Stocks That Can Bounce Back This Week ↗

March 10, 2025

These three stocks tumbled by at least 20% last week, but they may not be down for long.

Via The Motley Fool

MarketBeat Week in Review – 03/03 - 03/07

March 08, 2025

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue

Via MarketBeat

Topics Economy

This Could Be a Huge Blow to Hims & Hers Health Stock ↗

March 07, 2025

Via The Motley Fool

Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It ↗

March 05, 2025

Via The Motley Fool

Why Is Hims & Hers Health Stock Trading Lower On Wednesday? ↗

March 05, 2025

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy.

Via Benzinga

Novo Nordisk Slashes Wegovy Price, Undercutting Hims & Hers Health ↗

March 05, 2025

The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy.

Via Investor's Business Daily

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

47 48 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Search Hotels in Sausalito

Find A Business

or Browse Listings

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

All News about Hims & Hers Health, Inc. Class A Common Stock